Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA052051-05S1
Application #
2094573
Study Section
Special Emphasis Panel (SRC (C2))
Project Start
1991-08-05
Project End
1996-11-30
Budget Start
1995-06-01
Budget End
1996-11-30
Support Year
5
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Hildebrandt, Michelle A T; Lippman, Scott M; Etzel, Carol J et al. (2012) Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention. Clin Cancer Res 18:3705-13
Lee, J Jack; Wu, Xifeng; Hildebrandt, Michelle A T et al. (2011) Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. Cancer Prev Res (Phila) 4:185-93
Wang, Jianming; Lippman, Scott M; Lee, J Jack et al. (2010) Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma. Carcinogenesis 31:1755-61
Zhang, Xiaofan; Yang, Hushan; Lee, J Jack et al. (2010) MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer. Carcinogenesis 31:2118-23
Wu, Xifeng; Spitz, Margaret R; Lee, J Jack et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev Res (Phila) 2:617-24
William Jr, William N; Lee, J Jack; Lippman, Scott M et al. (2009) High-dose fenretinide in oral leukoplakia. Cancer Prev Res (Phila) 2:22-6
Papadimitrakopoulou, Vassiliki A; Lee, J Jack; William Jr, William N et al. (2009) Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy. J Clin Oncol 27:599-604
Kawaguchi, Hidetoshi; El-Naggar, Adel K; Papadimitrakopoulou, Vali et al. (2008) Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 26:354-60
Wu, Xifeng; Gu, Jian; Dong, Qiong et al. (2006) Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. Clin Cancer Res 12:7194-201
Lippman, Scott M; Lee, J Jack (2006) Reducing the ""risk"" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture. Cancer Res 66:2893-903

Showing the most recent 10 out of 91 publications